Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03144622
18F-FSPG PET/CT Imaging in Patients With Cancers
Overview
This study aims to compare the diagnostic performance of 18F-FDG and 18F-FSPG PET/CT in lung, breast, and abdominal cancers before undergoing therapy. In addition, the role of 18F-FSPG PET/CT in evaluating therapy response and prognosis will also be evaluated.
Sponsor
National Taiwan University Hospital
Contacts
Mei-Fang Cheng, MD (CONTACT)
meifang@ntuh.gov.tw
886-02-23123456
Mei-Fang Cheng, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT03144622Drug / Compound
FDG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Glucose Transport
Ligand Class: Small Molecules
FSPG
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Cystine/glutamate antiporter
Ligand Class: Small Molecules
Eligibility
Inclusion
- Sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks.
- Life expectancy \> 3 months.
- Consent to perform additional 18F-FSPG and 18F-FDG PET prior to therapy.
- ECOG performance status 0 to 2.
- Patients are given the opportunity to participate in the study if
- Confirmed diagnosis of primary cancer of the following: NSCLC, breast or abdominal cancers
Exclusion
- Had received previous treatment (excluding neoadjuvant therapy).
- Known malignancy in other organs.
- Known hypersensitivity to the study drug.
- Pregnant or lactating women.
- Patients with any of the following conditions will be excluded
- Evaluated by primary care physician as unsuitable.
Share your feedback
Help us improve your experience